Compare Becton Dickinson and Co (BDX) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Citius Pharmaceuticals Inc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $42.39B), while Citius Pharmaceuticals Inc trades at $0.52 (market cap $14.83M). The key difference: Becton Dickinson and Co is far larger — about 2858.4× Citius Pharmaceuticals Inc's market cap, and Becton Dickinson and Co pays a 2.73% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BDX | CTXR | |
|---|---|---|
Market Cap | $42.39B | $14.83M |
Sector | Health | Health |
52-Week High | $185.39 | $1.82 |
52-Week Low | $135.49 | $0.53 |
Enterprise Value | $58.85B | $11.05M |
Dividend Yield | 2.73% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
